Uma série de compostos 6-arilbenzimidazo[1,2-c]quinazolina (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) foram sintetizados pela condensação do 2-(o-aminofenil)benzimidazol com diferentes arilaldeídos seguida pela ciclização oxidativa dos 2-o-arilidenoaminofenilbenzimidazol (1-10). Todos os produtos foram caracterizados por espectroscopia no infravermelho (IR), ressonância magnética nuclear de prótons e de carbono, (RMN 1 H e RNN 
Introduction
Heterocycles have a central position in medicinal as well as in organic chemistry [1] [2] [3] and considerable attention has been focused on their syntheses. Nitrogen heterocycles in particular exhibit diverse biological and pharmacological activities [4] [5] [6] due in part to the similarities with many natural and synthetic molecules with known biological activity. 7 Moreover, benzimidazoles and quinazolines are of the most extensively studied classes of heterocyclic compounds, and have received much attention from synthetic organic as well as medicinal chemists, because of the diverse range of their biological activities 8, 9 and their applications in several areas as materials in electronics, in electrochemistry as anticorrosive agents, as polymers or optical materials and fluorescent tags in DNA sequencing. [10] [11] [12] In general, quinazoline compounds have been well-recognized for their pharmacological properties, such as anti-inflammatory, 13, 14 antihypertensive, 15 anti-HIV, 16 bronco-dilatory, 17 antiallergic, 18 anti-cancer, [19] [20] [21] anticonvulsant, 22, 23 antihelmintic, 24 analgesic, 25 antimalarial 26 and antimicrobial 27 activities. Literature survey reveals that, benzimidazo [1,2-c] quinazoline derivatives also show various biological activities, 23, [28] [29] [30] such as anticancer, antiviral, antimicrobial, anti-inflammatory and anticonvulsants. However, search is continuously on to identify a more potent lead molecule as these molecules are developing resistance over a period. Based on the importance of these molecules, our attention was attracted towards synthesis of novel quinazoline derivatives in order to find more potent biologically active molecules. Hence, we report here the synthesis and characterization of new 6-arylbenzimidazo[1,2-c]quinazoline compounds (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . In addition, the antimicrobial activities of all synthesized quinazolines against different bacteria and fungi were evaluated. Among the compounds tested some of quinazolines were found to be superior in inhibiting all the bacterial and fungal strains.
Results and Discussion

Chemistry
The condensation of o-phenylenediamine with anthranilic acid was carried out in presence of polyphosphoric acid at 250 °C for 4 h to obtain the known 2-(o-aminophenyl) benzimidazole (A) (mp 214 o C). 31 The target compounds were prepared by using the reaction sequence in Scheme 1. Initially, we synthesised ten new 2-o-arylideneaminophenylbenzimidazoles (1-10) via the condensation between 2-(o-aminophenyl b e n z i m i d a z o l e(A ) a n d va r i o u s a r y l al d e hy d e s . At last, we prepared 6-arylbenzimidazo [1,2-c] quinazolines (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) through oxidative cyclisation 32 of 2-o-arylideneaminophenylbenzimidazoles (1-10).
IR spectra of compound A showed absorption band at 3350 cm -1 assigned to aminophenyl ring and in the case of compounds A and 1-10 two absorption bands in the region 3150-3300 cm -1 and 1420 cm -1 were assigned to -NH stretching and bending vibrations of imidazolyl ring, respectively. 33, 34 The absence of aminophenyl ring absorption at 3350 cm -1 and appearance of a strong intensity band in the IR spectra of compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) in the range of 1610-1650 cm -1 attributable to nC=N provides a strong evidence for the condensation and also confirms the formation of the azomethines 1-10. 35 The oxidative cyclisation of compounds 1-10 to 11-20 were accompanied by the disappearance of the absorption maxima at 3150-3300 cm -1 , which are ascribed to the vibrations of NH group of the benzimidazole ring; at the same time the appearance of a new maximum at 1360-1388 cm --1 , which is characteristic for benzimidazoquinazoline ring with a tertiary nitrogen atom, appears. 23, 36 The 1 H NMR spectra of the compound A as well as its derivatives have been recorded in CDCl 3 /DMSO-d 6 using TMS as internal standard. In the spectra of 2-(o-aminophenyl) benzimidazole (A), signals at d 6.4 and d 8.25 ppm were appeared corresponding to free amino and imidazolyl protons respectively. 33, 35 The aromatic protons of various environments present in all compounds appeared as multiplets in the range of d 6.84-8.81 ppm.
35,37
1 H NMR spectra of compounds 1-10 contain signals corresponding to CH=N protons in the range of d 8.07-8.29 ppm suggesting the condensation of aromatic aldehydes with compound A. However, in the spectra of 1-10 compounds the disappearance of signals at d 6.4 ppm which is due to NH 2 protons of compound A supports the involvement of amino group in condensation and confirms the formation of azomethines. Finally, in the spectra of 11-20 compounds disappearance of signals corresponding to -NH of imidazolyl ring and CH=N protons supports the benzimidazoquinazoline ring structure. 37 The 1 H and 13 C NMR spectra ( Figure S2 and Figure S3 ) of compound 20 are given in supplementary material.
All the compounds (except 2 and 12) showed a single peak in ESI-MS suggesting the molecular formulae of the azomethines and quinazolines. 
Biological study
Antimicrobial activity
The in vitro antimicrobial activity was carried out by cupplate method. 38 All the synthesized quinazolines were screened for antibacterial activity against Staphylococcus aureus, Bacillus subtilis, Streptococcus pyogenes (Gram positive) and Salmonella typhimurium, Escherichia coli, Klebsiella pneumonia (Gram negative) bacterial strains using ampicillin as standard. The antifungal activity was investigated against Aspergillus niger, Candida albicans, Trichoderma viridae fungal strains using ketoconazole as standard. Preliminary screening of target compounds and standard drugs were performed at fixed concentrations of 1000 µg mL -1 . Inhibition was recorded by measuring the diameter of the inhibition zone at the end of 48 h for bacteria and 72 h for fungi. Each experiment was repeated thrice and the average of the three independent determinations was recorded. Screening results are summarized in Table 1 . Among the compounds tested 13 was found to exhibit good activity against all bacterial and fungal strains. Furthermore, the most potent activity was observed in 19 and 20 against all bacterial and fungal strains when compared to respective standard drugs ampicillin and ketoconazole. The minimum inhibitory concentration 39 of these quinazolines (13, 19 and 20) was also verified by the liquid dilution method in which the effectiveness was observed at lower concentrations. The detailed antibacterial and antifungal preliminary screening methods are given in supplementary material.
Determination of minimum inhibitory concentration (MIC)
The 35, 40, 45 and 50 µg mL -1 concentrations were prepared with appropriate solvent. The solutions of standard drugs, ampicillin and ketoconazole were prepared in the same concentrations. Inoculums of the bacterial and fungal culture were also prepared. To a series of tubes containing 1 mL each of quinazoline compound solution with different concentrations and 0.2 mL of the inoculum was added. Further 3.8 mL of the sterile water was added to each of the test tubes. These test tubes were incubated for 24 h and observed for the presence of turbidity. This method was repeated by changing quinazoline compounds with standard drug ampicillin (in case of bacteria) and with ketoconazole (in case of fungi) for comparison.The minimum inhibitory concentration at which no growth was observed was taken as the MIC values. Comparison of MIC values (in µg mL and ketoconazole towards inhibiting all tested bacterial and fungal strains.
Conclusions
Quinazolines and related derivatives are classes of heterocyclic compounds contain the pyrimidine nucleus in their structures. Literature survey reveals that a variety of antimicrobial agents contains quinazoline moiety and also fused quinazoline ring systems such as benzimidazoloquinazolines, indoloquinazolines and many other. In a search for new fused quinazoline systems with potential biological activities, we planned to prepare new 6-arylbenzimidazo[1,2-c]quinazolines, from 2-(o-aminophenyl) benzimidazole and various aldehydes as starting compounds. We have chosen six bacterial and three fungal strains for microbial studies of these entire quinazoline compounds. From this study it is evident that all quinazoline compounds are showing moderate to good activity towards inhibiting all tested bacterial 
Experimental
Analar grade reagents and freshly distilled solvents were used throughout the investigations. Compounds were checked for their purity by TLC using Merck 60 F 254 silica gel plates and spots were located by iodine vapors. Micro analytical (C, N, H) data was obtained by using a Perkin-Elmer 2400 CHN elemental analyzer. The IR spectra were recorded in KBr pellets on Perkin-Elmer-283 spectrophotometer. 
Preparation of 2-(o-aminophenyl)benzimidazole [BIPhNH 2 ] (A)
2-(o-aminophenyl) benzimidazole (A) was prepared by reacting orthophenylenediamine (OPD) with anthranillic acid in freshly prepared polyphosphoric acid (PPA) acid at 250 °C for 4 h.
Procedure for preparation of mono-2-o-(arylideneamino) phenyl benzimidazoles (1-10)
To a hot stirred solution of 2-(o-aminophenyl) benzimidazole (A) (2 mmol) in ethanol (20 mL) were added the appropriate aldehyde (2 mmol) and 2-3 drops of acetic acid. The resultant mixture was refluxed under heat (40-55 °C) for 2 h after which the compound was obtained. The product was filtered and recrystalized from a dichloromethane-methanol mixture.
Procedure for preparation of 6-arylbenzimidazo [1,2-c] quinazolines [BIQ-Ar] (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) All the 6-arylbenzimidazo[1,2-c]quinazolines (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) were prepared from azomethines 1-10 through oxidative cyclisation method reported by Davis and Mann. 32 Powdered potassium permanganate (1.5 equiv.) was added to a solution of the azomethyne compound (1-10) in 50-75 mL of acetone. The mixture was boiled (40-80 °C) under reflux for 30 min. It was then filtered hot, and an equal volume of hot water added to the filtrate. The quinazolines (11-20) rapidly separated, and was collected by filtration and recrystalized from dimethylformamide. All the synthesized compounds were characterized as given below.
2-(o-Aminophenyl)benzimidazole [BIPhNH 2 ] (A)
Yield 
2-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl) phenol (1)
Yield 81%; mp 288-290 °C; IR n max /cm 
2-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl)-4-bromophenol (2)
Yield 79%; mp 318-320 °C; IR n max /cm 
2-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl)-4-nitrophenol (3)
Yield 81%; mp 255-257 °C; IR n max /cm 
2-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl)-4-methoxyphenol (4)
Yield 80%; mp 285-287 °C; IR n max /cm 
3-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl) benzoic acid (5)
Yield 76%; mp 226-228 °C; IR n max /cm 
3-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl)-4-hydroxybenzoic acid (6)
Yield 79%; mp 315-317 °C; IR n max /cm 
4-([2-(1H-Benzo[d]imidazol-2-yl)phenyl]iminomethyl)-2,6-dimethylphenol (7)
Yield 78%; mp 211-213 °C; IR n max /cm 
N1-[(E)-1-(3,5-Dimethoxyphenyl)methylidene]-2-(1H-benzo[d]imidazol-2-yl) aniline (8)
Yield 75%; mp 228-230 °C; IR n max /cm 
N1-[(E)-1-(1-Isoquinolyl)methylidene]-2-(1H-benzo[d] imidazol-2-yl)aniline (9)
Yield 81%; mp 254-256 °C ; IR n max /cm 
N1-[(E)-1-(3-Pyridyl)methylidene]-2-(1H-benzo[d] imidazol-2-yl)aniline (10)
Yield 79%; mp 230-232 °C; IR n max /cm 2-Benzo [4, 5] imidazo [1,2-c] quinazolin-6-ylphenol (11) Yield 82%; mp 300-302 °C; IR n max /cm 
-B e n z o [ 4 , 5 ] i m i d a z o [ 1 , -c ] q u i n a z o l i n -6 -y l -4 -bromophenol (12)
Yield 75%; mp 330-332 °C; IR n max /cm [4, 5] imidazo [1,2- 
2-Benzo
-B e n z o [ 4 , 5 ] i m i d a z o [ 1 , -c ] q u i n a z o l i n -6 -y l -4 -methoxyphenol (14)
Yield 81%; mp 300-302 °C; IR n max /cm [4, 5] imidazo [1,2- 
3-Benzo
-B e n z o [ 4 , 5 ] i m i d a z o [ 1 , 2 -c ] q u i n a z o l i n -6 -y l -4 -hydroxybenzoic acid (16)
Yield 78%; mp 342-344 °C; IR n max /cm [4, 5] imidazo [1,2-c] [4, 5] imidazo [1,2-c] quinazoline (18) Yield 75%; mp 235-237 °C; IR n max /cm ) at m/z 355.
4-Benzo
6-(1-Isoquinolyl)benzo [4, 5] imidazo [1,2-c] [4, 5] imidazo [1,2-c] 
6-(3-Pyridyl)benzo
Supplementary Information
Spectral data of compounds are available free of charge at http://jbcs.sbq.org.br, as pdf file. Scheme S1. FAB mass fragmentation pattern of 6-(3-pyridyl)benzo [4, 5] imidazo [1,2-c] quinazoline (20) .
